Factors Affecting Tacrolimus Concentrations in Children with β-Thalassemia Major receiving HSCT

Article
ASTCT

ASTCT recently published an article in their journal Nucleus detailing the impact of genotype and voriconazole co-administration on tacrolimus trough concentration in pediatric β-thalassemia major patients following allogeneic hematopoietic stem cell transplantation.

The following was recently published in ASTCT’s Nucleus publication. Follow @ATSTCT for the latest on all-things cellular therapy.

In a study published in Pharmacogenomics and Personalized Medicine, researchers investigated the impacts of genotype and voriconazole co-administration on tacrolimus (TAC) trough concentration (C0) in pediatric β-thalassemia major (β-TM) patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT). The authors' findings stress the importance of tailoring drug administration based on patients' genotype profiles, as well as tracking patients' TAC concentrations when administering voriconazole.

For patients receiving allo-HSCT, there is a risk of developing graft versus host disease (GVHD) following transplantation. β-TM patients are therefore at risk of GVHD, as allo-HSCT is currently the sole procedure for curing β-TM. TAC has been utilized as a prophylactic following allo-HSCT, but the effects of its concentration alongside patients' genotypes and co-administration of voriconazole has not been well studied.

Patients were administered TAC two days before allo-HSCT, with venous blood samples collected to determine concentrations before and after transplantation. The results concluded that variations in enzymes such as CYP3A4 greatly impacted TAC concentrations when administered orally. Moreover, the co-administration of voriconazole was found to increase TAC concentrations, necessitating lower TAC doses. Lastly, TAC C0 was found to not be highly correlated with efficacy in these patients, suggesting that C0 is not suitable as an indicator of the efficacy of TAC.

Reference

Li C, Lu J, Zhou S, et al. Influential factors and efficacy analysis of tacrolimus concentration after allogeneic hematopoietic stem cell transplantation in children with β-thalassemia major. Pharmgenomics Pers Med. 2021;14:1221-1237. Published 2021 Sep 24. doi:10.2147/PGPM.S325103

Related Videos
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.